SpecificDioscoreaPhytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines | Zendy

WeiTing Chang | Zendy; Hui-Ming Chen | Zendy; ShuYi Yin | Zendy; YungHsiang Chen | Zendy; Chih-Chun Wen | Zendy; WenChi Wei | Zendy; Phoency Lai | Zendy; ChengHsin Wang | Zendy; NingSun Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SpecificDioscoreaPhytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines

Author(s) -

WeiTing Chang,

Hui-Ming Chen,

ShuYi Yin,

YungHsiang Chen,

Chih-Chun Wen,

WenChi Wei,

Phoency Lai,

ChengHsin Wang,

NingSun Yang

Publication year - 2013

Publication title -

evidence-based complementary and alternative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.552

H-Index - 90

eISSN - 1741-4288

pISSN - 1741-427X

DOI - 10.1155/2013/932040

Subject(s) - cd86 , adjuvant , in vivo , ex vivo , t cell , dendritic cell , population , cd80 , chemistry , bone marrow , cancer research , immune system , biology , immunology , cd40 , biochemistry , in vitro , medicine , cytotoxic t cell , microbiology and biotechnology , environmental health

Dioscorea tuber phytoextracts can confer immunomodulatory activities ex vivo and improve regeneration of bone marrow cells in vivo . In present study, we evaluated specific Dioscorea phytoextracts for use ex vivo as a bone-marrow-derived dendritic cell- (DC-) based vaccine adjuvant for cancer immunotherapy. Fractionated Dioscorea extracts (DsII) were assayed for their effect on maturation and functions of DC ex vivo and antimelanoma activity of DC-based vaccine in vivo . The phytoextract from 50–75% ethanol-precipitated fraction of Dioscorea alata var. purpurea Tainung no. 5 tuber, designated as DsII-TN5, showed a strong augmentation of tumor cell lysate- (TCL-) loaded DC-mediated activation of T-cell proliferation. DsII-TN5 stimulated the expression of CD40, CD80, CD86, and IL-1 β in TCL-loaded DCs and downregulated the expression of TGF- β 1. DC vaccines prepared by a specific schema (TCL (2 h) + LPS (22 h)) showed the strongest antitumor activity. DsII-TN5 as a DC vaccine adjuvant showed strong antimelanoma activity and reduced myeloid-derived suppressor cell (MDSC) population in tested mice. DsII-TN5 can also activate DCs to enhance Th1- and Th17-related cytokine expressions. Biochemical analysis showed that DsII-TN5 consists mainly of polysaccharides containing a high level (53%) of mannose residues. We suggest that DsII-TN5 may have potential for future application as a potent, cost-effective adjuvant for DC-based cancer vaccines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research